Incyte Corp. Stock Underperforms Friday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.
Incyte Corp. (INCY) shares fell 2.38% to $95.31 on Friday, marking the fourth consecutive day of losses. The stock is 15.12% below its 52-week high of $112.29. In comparison, competitors like Alnylam Pharmaceuticals, Bio-Techne, and BioMarin also experienced declines. The overall market was down, with the S&P 500 and Dow Jones falling 1.24% and 1.07%, respectively.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: MarketWatch Automated The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments